minimum bmi for glp 1 Patients with Higher Initial BMIs and Greater Weight Loss While on GLP-1s Most Likely to Maintain or Continue Weight Loss After Stopping GLP-1s BMI Qualifications for Semaglutide and

Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum

Dennys et al., 2023)

At CSLC, filler isn't about brand loyalty

Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab 24(6):795806

One trial compared once-weekly subcutaneous semaglutide with once-weekly subcutaneous exenatide extended release (Byetta, AstraZeneca), one compared once-weekly subcutaneous semaglutide with once-daily liraglutide (Saxenda, Novo Nordisk), a third compared once-daily oral semaglutide with liraglutide, another trial compared once-weekly subcutaneous semaglutide with once-weekly subcutaneous dulaglutide (Trulicity, Eli Lilly) and the fifth compared once-daily oral semaglutide with dulaglutide

Below is a clinical framework of gastrointestinal effects reported across GLP-1 clinical trials and real-world use